Abstract |
Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine. In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. Improvement lasted 2 to 3 hours. Lisuride had little or no effect in a single patient with progressively supranuclear palsy. Oral lisuride therapy, 0.8 to 4.8 mg daily, had similar effects but occasionally caused reduced awareness and hallucinations.
|
Authors | J D Parkes, M Schachter, C D Marsden, B Smith, A Wilson |
Journal | Annals of neurology
(Ann Neurol)
Vol. 9
Issue 1
Pg. 48-52
(Jan 1981)
ISSN: 0364-5134 [Print] United States |
PMID | 7212665
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Benzimidazoles
- Ergolines
- Piperidines
- Domperidone
- Prolactin
- Growth Hormone
- Lisuride
|
Topics |
- Administration, Oral
- Aged
- Benzimidazoles
(administration & dosage)
- Chorea
(chemically induced)
- Domperidone
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Dyskinesia, Drug-Induced
(etiology)
- Ergolines
(therapeutic use)
- Female
- Growth Hormone
(blood)
- Humans
- Injections, Intravenous
- Lisuride
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Paralysis
(drug therapy)
- Parkinson Disease
(drug therapy)
- Parkinson Disease, Postencephalitic
(drug therapy)
- Parkinson Disease, Secondary
(chemically induced)
- Piperidines
(administration & dosage)
- Prolactin
(blood)
|